Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 2 mg/ml - oral liquid, solution - excipient ingredients: methyl hydroxybenzoate; purified water; propyl hydroxybenzoate; lactic acid - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; calcium hydrogen phosphate dihydrate; brilliant scarlet 4r - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; quinoline yellow; calcium hydrogen phosphate dihydrate; green s - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; calcium hydrogen phosphate dihydrate - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - thiomersal; selenium as sodium selenate; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid - parenteral liquid/solution/suspension - thiomersal mercury active 0.13 mg/ml; selenium as sodium selenate mineral-selenium active 0.5 mg/ml; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 3.5 iu/ml; clostridium perfringens type d toxoid vaccine-toxoid active 5.0 iu/ml; clostridium septicum - toxoid vaccine-toxoid active 2.5 iu/ml; clostridium tetani - toxoid vaccine-toxoid active 2.5 iu/ml - immunotherapy - lamb | ovine - black disease | blackleg | enterotoxaemia (pulpy kidney) | malignant oedema | selenium deficiency | tetanus | unthriftiness | white muscle disease | clostridium perfringens type d | ill - thrift | selenium deficiency | selenium responsive ill-thrift | stiff lamb disease | subacute enzootic muscular dys | tetanus vaccination | white muscle disease

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - hydroxocobalamin acetate; moxidectin; moxidectin concentrate; selenium as sodium selenate; blackleg = clostridium chauvoei; enterotoxaemia = pulpy kidney = c perfringens; clostridium novyi type b; malignant oedema = clostridium septicum; cla = corynebacterium pseudotuberculosis ovis; tetanus = clostridium tetani; thiomersal - parenteral liquid/solution/suspension - hydroxocobalamin acetate vitamin-b12 active 1.0 mg/ml; moxidectin anthelmintic active 2.5 mg/ml; moxidectin concentrate anthelmintic active 0.0 undefined; selenium as sodium selenate mineral-selenium active 0.5 mg/ml; blackleg = clostridium chauvoei vaccine-microbial active 0.0 undefined; enterotoxaemia = pulpy kidney = c perfringens vaccine-microbial active 0.0 undefined; clostridium novyi type b vaccine-microbial active 0.0 undefined; malignant oedema = clostridium septicum vaccine-microbial active 0.0 undefined; cla = corynebacterium pseudotuberculosis ovis vaccine-microbial active 0.0 undefined; tetanus = clostridium tetani vaccine-toxoid active 0.0 undefined; thiomersal mercury other 0.13 mg/ml - immuno+parasite+nutrition - lamb | ovine - barber's pole worm-haemonchus contortus | black scour worm - trichostrongylus spp. | brown stomach worm - ostertagia lyrata | cooperia curticei | cooperia oncophora | intestinal hair worm - t. colubriformis | intestinal threadworm - s. papillosus | large bowel worm - o. venulosum | large lungworm - dictyocaulus filaria | large mouthed bowel worm | nasal bot | nematodirus abnormalis | nematodirus battus | nematodirus filicollis | nematodirus helvetianus | nodule worm - o. columbianum | ostertagia circumcincta | ostertagia trifurcata | sheep itch mite | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | stomach hair worm | thin necked intestinal worm | thin necked intestinal worm-n. spathiger | trichostrongylus rugatus | trichostrongylus vitrinus | whipworm - trichuris ovis | black scour worm | psorobia ovis | sheep nasal bot fly | small brown stomach worm | small intestinal worm | teladorsagia | thin necked intestinal worm | thin necked intestinal worm-ad | trichostrongylus colu

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - hydroxocobalamin acetate; selenium as sodium selenate - parenteral liquid/solution/suspension - hydroxocobalamin acetate vitamin-b12 active 2.0 mg; selenium as sodium selenate mineral-selenium active 4.0 mg - nutrition & metabolism - cattle | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | heifer | h - selenium deficiency | vitamin b12 deficiency | anaemia | cobalt deficiency | white muscle disease

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - bacillus amyloliquefaciens strain qst 713 - wettable powder - bacillus amyloliquefaciens strain qst 713 biological-organism active 10.0 cfu/g - fungicide

New Zealand - English - myHealthbox

bayer ag - suspension concentrate - biologics

South Africa - English - myHealthbox

bayer ag - bacillus subtilis strain qst 713 1,34 % (w/w)